Important Information for Investors: Securities Class Action Lawsuit Filed Against Neumora Therapeutics, Inc.
RADNOR, Pa., March 16, 2025
The law firm of Kessler Topaz Meltzer & Check, LLP, announces that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. (Neumora) on behalf of investors who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the company’s prospectus and registration statement (collectively, the “Offering Documents”) issued in connection with Neumora’s initial public offering (IPO) held on or around September 15, 2023.
Background
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of cannabinoid therapeutics for the treatment of various diseases and conditions. The company’s mission is to bring innovative, science-driven solutions to patients in need.
The Lawsuit
The complaint alleges that Neumora and certain of its executives and directors made false and misleading statements and failed to disclose material information in the Offering Documents and during the IPO process, thereby artificially inflating the price of Neumora’s common stock.
Allegations
- The complaint alleges that Neumora failed to disclose material information regarding the company’s clinical trial data and regulatory issues with its lead product, NM-001, which is being developed for the treatment of chronic pain.
- Additionally, the complaint alleges that Neumora failed to disclose material information regarding the company’s financial condition, including its reliance on a single customer for a significant portion of its revenue.
Implications for Individual Investors
If you purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents issued in connection with Neumora’s IPO held on or around September 15, 2023, you may be entitled to recover your investment losses. Please contact Kessler Topaz Meltzer & Check, LLP, to learn more about your rights.
Impact on the Biopharmaceutical Industry
The securities class action lawsuit against Neumora Therapeutics, Inc. highlights the importance of transparency and accuracy in the communication of clinical trial data and financial information in the biopharmaceutical industry. Such disclosures are crucial for investors to make informed decisions and assess the risks and potential rewards of investing in a company.
Conclusion
The securities class action lawsuit filed against Neumora Therapeutics, Inc. serves as a reminder to investors to be vigilant in their due diligence efforts and to hold companies accountable for providing accurate and complete information. The outcome of this case could have significant implications for the biopharmaceutical industry and the investing public.
For more information about this class action, or to discuss your potential recovery, please contact Kessler Topaz Meltzer & Check, LLP:
- Kessler Topaz Meltzer & Check, LLP
- 280 King of Prussia Road, Radnor, PA 19087
- Phone: (888) 299-0718
- Email: [email protected]
